$LXRX
LEXICON PHARMACEUTICALS, INC. Stock $lxrx

$lxrx Overview Financials Valuation SEC Filings Company Website

2017 Q3 Form 10-Q Financial Statement

#000106282217000046 Filed on August 01, 2017

Income Statement

Concept	2017 Q3	2017 Q2	2016 Q2
Revenue	$27.67M	$12.09M	$20.09M
YoY Change	-0.16%	-39.83%	5242.82%
Cost Of Revenue	$599.0K	$537.0K	$0.00
YoY Change
Gross Profit	$27.08M	$11.55M	$20.09M
YoY Change	-2.32%	-42.51%
Gross Profit Margin	97.84%	95.56%	100.0%
Selling, General & Admin	$16.72M	$18.48M	$8.416M
YoY Change	36.38%	119.52%	33.59%
% of Gross Profit	61.77%	159.96%	41.89%
Research & Development	$39.14M	$26.93M	$48.22M
YoY Change	-25.5%	-44.14%	132.15%
% of Gross Profit	144.55%	233.19%	240.01%
Depreciation & Amortization	$900.0K	$1.000M	$500.0K
YoY Change	80.0%	100.0%	150.0%
% of Gross Profit	3.32%	8.66%	2.49%
Operating Expenses	$56.46M	$45.95M	$57.11M
YoY Change	-9.88%	-19.55%	111.02%
Operating Profit	-$28.61M	-$33.49M	-$37.02M
YoY Change	-18.11%	-9.54%	38.72%
Interest Expense	$1.619M	$1.614M	$1.638M
YoY Change	-1.64%	-1.47%	-1.03%
% of Operating Profit
Other Income/Expense, Net	$415.0K	$448.0K	$547.0K
YoY Change	-26.42%	-18.1%	103.35%
Pretax Income	-$30.72M	-$35.06M	-$38.11M
YoY Change	-14.7%	-8.01%	35.63%
Income Tax	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$29.81M	-$34.66M	-$38.11M
YoY Change	-17.23%	-9.07%	35.76%
Net Earnings / Revenue	-107.71%	-286.73%	-189.72%
Basic Earnings Per Share
Diluted Earnings Per Share	-$290.7K	-$333.3K	-$367.1K
COMMON SHARES
Basic Shares Outstanding	105.6M shares	105.2M shares	103.8M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2017 Q3	2017 Q2	2016 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$196.8M	$231.2M	$429.4M
YoY Change	-50.25%	-46.16%	52.22%
Cash & Equivalents	$83.29M	$30.71M	$38.41M
Short-Term Investments	$113.5M	$200.5M	$391.0M
Other Short-Term Assets	$4.458M	$10.17M	$9.071M
YoY Change	82.48%	12.16%	26.85%
Inventory	$2.149M	$811.0K
Prepaid Expenses
Receivables	$10.60M	$5.014M	$1.018M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$214.0M	$247.2M	$439.5M
YoY Change	-46.33%	-43.75%	40.04%
LONG-TERM ASSETS
Property, Plant & Equipment	$18.17M	$18.59M	$20.35M
YoY Change	-8.5%	-8.66%	2875.15%
Goodwill	$44.54M	$44.54M	$44.54M
YoY Change	0.0%	0.0%	0.0%
Intangibles	$52.33M	$52.77M	$53.36M
YoY Change	-1.93%	-1.1%	0.0%
Long-Term Investments
YoY Change
Other Assets	$429.0K	$428.0K	$430.0K
YoY Change	-5.51%	-0.47%	-87.99%
Total Long-Term Assets	$115.5M	$116.3M	$118.7M
YoY Change	-2.32%	-1.98%	16.17%
TOTAL ASSETS
Total Short-Term Assets	$214.0M	$247.2M	$439.5M
Total Long-Term Assets	$115.5M	$116.3M	$118.7M
Total Assets	$329.5M	$363.5M	$558.1M
YoY Change	-36.26%	-34.87%	34.18%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$52.63M	$43.86M	$28.23M
YoY Change	26.68%	55.38%	149.98%
Accrued Expenses	$12.73M	$10.96M	$23.95M
YoY Change	-61.32%	-54.24%	121.62%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$14.63M	$15.16M	$17.29M
YoY Change	-12.86%	-12.34%	-10.21%
Total Short-Term Liabilities	$128.7M	$133.2M	$131.0M
YoY Change	-24.33%	1.66%	200.64%
LONG-TERM LIABILITIES
Long-Term Debt	$85.51M	$85.38M	$84.91M
YoY Change	0.56%	0.56%	-2.96%
Other Long-Term Liabilities	$303.0K	$313.0K	$14.04M
YoY Change	-87.88%	-97.77%	-39.06%
Total Long-Term Liabilities	$85.82M	$85.70M	$98.95M
YoY Change	-1.97%	-13.39%	-10.49%
TOTAL LIABILITIES
Total Short-Term Liabilities	$128.7M	$133.2M	$131.0M
Total Long-Term Liabilities	$85.82M	$85.70M	$98.95M
Total Liabilities	$251.1M	$257.2M	$340.8M
YoY Change	-24.31%	-24.53%	84.73%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.353B	-$1.322B	-$1.182B
YoY Change	11.09%	11.88%	1.86%
Common Stock	$106.0K	$105.0K	$104.0K
YoY Change	1.92%	0.96%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$1.904M	$1.904M	$3.368M
YoY Change	-43.47%	-43.47%	22.61%
Treasury Stock Shares	122.0K shares	122.0K shares	306.0K shares
Shareholders Equity	$78.38M	$106.3M	$217.3M
YoY Change
Total Liabilities & Shareholders Equity	$329.5M	$363.5M	$558.1M
YoY Change	-36.26%	-34.87%	34.18%

Cashflow Statement

Concept	2017 Q3	2017 Q2	2016 Q2
OPERATING ACTIVITIES
Net Income	-$29.81M	-$34.66M	-$38.11M
YoY Change	-17.23%	-9.07%	35.76%
Depreciation, Depletion And Amortization	$900.0K	$1.000M	$500.0K
YoY Change	80.0%	100.0%	150.0%
Cash From Operating Activities	-$34.00M	-$32.20M	-$47.90M
YoY Change	-3.41%	-32.78%	48.76%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	-$100.0K	$0.00
YoY Change			-100.0%
Acquisitions
YoY Change
Other Investing Activities	$87.10M	$56.90M	$61.60M
YoY Change	156.93%	-7.63%	7600.0%
Cash From Investing Activities	$87.10M	$56.70M	$61.50M
YoY Change	156.93%	-7.8%	20400.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-500.0K	3.700M	0.000
YoY Change	-129.41%		-100.0%
NET CHANGE
Cash From Operating Activities	-34.00M	-32.20M	-47.90M
Cash From Investing Activities	87.10M	56.70M	61.50M
Cash From Financing Activities	-500.0K	3.700M	0.000
Net Change In Cash	52.60M	28.20M	13.60M
YoY Change	13050.0%	107.35%	-142.11%
FREE CASH FLOW
Cash From Operating Activities	-$34.00M	-$32.20M	-$47.90M
Capital Expenditures	$0.00	-$100.0K	$0.00
Free Cash Flow	-$34.00M	-$32.10M	-$47.90M
YoY Change	-3.41%	-32.99%	51.1%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	105581456	shares
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	LEXICON PHARMACEUTICALS, INC./DE
CY2017Q1	lxrx	Accumulated Excess Tax Benefits Recognizedas Deferred Tax Assets AccumulatedExcessTaxBenefitsRecognizedasDeferredTaxAssets	6100000	USD
CY2017Q1	lxrx	Adjustmentto Accumulated Deficit AdjustmenttoAccumulatedDeficit	2000000	USD
CY2017Q2	lxrx	Buildings Collateral BuildingsCollateral	59200000	USD
CY2016Q2	lxrx	Change In Fair Value Of Symphony Icon Inc Purchase Liability ChangeInFairValueOfSymphonyIconIncPurchaseLiability	478000	USD
	lxrx	Change In Fair Value Of Symphony Icon Inc Purchase Liability ChangeInFairValueOfSymphonyIconIncPurchaseLiability	1443000	USD
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
	dei	Document Period End Date DocumentPeriodEndDate	2017-06-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001062822
CY2017Q2	lxrx	Change In Fair Value Of Symphony Icon Inc Purchase Liability ChangeInFairValueOfSymphonyIconIncPurchaseLiability	0	USD
	lxrx	Change In Fair Value Of Symphony Icon Inc Purchase Liability ChangeInFairValueOfSymphonyIconIncPurchaseLiability	2101000	USD
CY2017Q2	lxrx	Convertible Debt Instrument Interest Rate Stated Percentage ConvertibleDebtInstrumentInterestRateStatedPercentage	0.0525
CY2007Q2	lxrx	Holdings Contribution To Icon HoldingsContributionToIcon	45000000	USD
CY2014Q4	lxrx	Ipsen Maximum Regulatory And Commercial Milestones IpsenMaximumRegulatoryAndCommercialMilestones	27000000	USD
CY2014Q4	lxrx	Ipsen Maximum Sales Milestones IpsenMaximumSalesMilestones	72000000	EUR
CY2016Q3	lxrx	Ipsen Milestone Payment IpsenMilestonePayment	6400000	USD
CY2014Q4	lxrx	Ipsen Revenue Allocatedto Committee Deliverable IpsenRevenueAllocatedtoCommitteeDeliverable	100000	USD
CY2014Q4	lxrx	Ipsen Revenue Allocatedto Development Deliverable IpsenRevenueAllocatedtoDevelopmentDeliverable	1700000	USD
CY2014	lxrx	Ipsen Revenue Allocatedto License Deliverable IpsenRevenueAllocatedtoLicenseDeliverable	21200000	USD
CY2015	lxrx	Ipsen Revenue Allocatedto License Deliverable IpsenRevenueAllocatedtoLicenseDeliverable	1400000	USD
	lxrx	Ipsen Revenue Recognized IpsenRevenueRecognized	200000	USD
	lxrx	Ipsen Revenue Recognized IpsenRevenueRecognized	1400000	USD
CY2017Q2	lxrx	Ipsen Total Payments IpsenTotalPayments	30900000	USD
CY2015Q1	lxrx	Ipsen Total Upfront Payments IpsenTotalUpfrontPayments	24500000	USD
	lxrx	Ipsenproductsales Ipsenproductsales	300000	USD
CY2017Q2	lxrx	Land Collateral LandCollateral	2700000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	5427000	USD
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	147400000	USD
	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	0	USD
	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	-7000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	988000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	1162000	USD
CY2010Q3	lxrx	Lexicon Paid Holdings Cash LexiconPaidHoldingsCash	10000000	USD
CY2015Q4	lxrx	Sanofi Revenue Allocatedto License Deliverable SanofiRevenueAllocatedtoLicenseDeliverable	126800000	USD
CY2007Q2	lxrx	Lexicon Received Cash From Holdings LexiconReceivedCashFromHoldings	15000000	USD
CY2007Q2	lxrx	Lexicon Sold Shares To Holdings LexiconSoldSharesToHoldings	1092946	shares
CY2015Q4	lxrx	Sanofi Commercialization Costs Fundedby Lexicon Maximum Amount SanofiCommercializationCostsFundedbyLexiconMaximumAmount	100000000	USD
CY2015Q4	lxrx	Sanofi Development Milestones SanofiDevelopmentMilestones	110000000	USD
CY2015Q4	lxrx	Sanofi Outcomes Study Milestone SanofiOutcomesStudyMilestone	100000000	USD
CY2015Q4	lxrx	Sanofi Regulatory Milestones SanofiRegulatoryMilestones	220000000	USD
CY2015Q4	lxrx	Sanofi Revenue Allocatedto Development Deliverable SanofiRevenueAllocatedtoDevelopmentDeliverable	113800000	USD
CY2015Q4	lxrx	Sanofi Revenue Allocatedto Funding Deliverable SanofiRevenueAllocatedtoFundingDeliverable	59400000	USD
	lxrx	Sanofi Revenue Recognized SanofiRevenueRecognized	31700000	USD
	lxrx	Sanofi Revenue Recognized SanofiRevenueRecognized	24100000	USD
CY2015Q4	lxrx	Sanofi Sales Milestone Payments SanofiSalesMilestonePayments	990000000	USD
CY2015Q4	lxrx	Sanofi Upfront Payment SanofiUpfrontPayment	300000000	USD
	lxrx	Share Based Compensation Arrangement By Share Based Payment Award Stock Bonus And Restricted Stock Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod	10248	shares
	lxrx	Share Based Compensation Arrangement By Share Based Payment Award Stock Bonus And Restricted Stock Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriodWeightedAverageGrantDateFairValue	15.61
	lxrx	Shares Issued To Symphony Designees Value SharesIssuedToSymphonyDesigneesValue	0	USD
	lxrx	Shares Issued To Symphony Designees Value SharesIssuedToSymphonyDesigneesValue	10499000	USD
CY2016Q2	lxrx	Stock Based Compensation Expense Associated With Research And Development Expense StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense	973000	USD
	lxrx	Stock Based Compensation Expense Associated With Research And Development Expense StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense	1962000	USD
CY2017Q2	lxrx	Stock Based Compensation Expense Associated With Research And Development Expense StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense	1169000	USD
	lxrx	Stock Based Compensation Expense Associated With Research And Development Expense StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense	2353000	USD
CY2016Q2	lxrx	Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense	984000	USD
	lxrx	Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense	1830000	USD
CY2017Q2	lxrx	Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense	1234000	USD
	lxrx	Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense	2281000	USD
CY2010Q3	lxrx	Symphon Fair Value Of Base And Contingent Payments SymphonFairValueOfBaseAndContingentPayments	45600000	USD
CY2016Q3	lxrx	Symphony Amendment Buyout SymphonyAmendmentBuyout	21000000	USD
CY2010Q3	lxrx	Symphony Base Payment Discount Rate SymphonyBasePaymentDiscountRate	0.14
CY2012Q3	lxrx	Symphony Base Payment In Shares SymphonyBasePaymentInShares	1891074	shares
CY2012Q3	lxrx	Symphony Base Payment Obligation SymphonyBasePaymentObligation	35000000	USD
CY2010Q3	lxrx	Symphony Contingent Payment Discount Rate SymphonyContingentPaymentDiscountRate	0.18
CY2014Q4	lxrx	Symphony Contingent Payment In Cash SymphonyContingentPaymentInCash	5800000	USD
CY2015Q2	lxrx	Symphony Contingent Payment In Cash SymphonyContingentPaymentInCash	750000	USD
CY2016Q3	lxrx	Symphony Contingent Payment In Cash SymphonyContingentPaymentInCash	3200000	USD
CY2017Q1	lxrx	Symphony Contingent Payment In Cash SymphonyContingentPaymentInCash	10500000	USD
CY2010Q3	lxrx	Symphony Contingent Payment Maximum SymphonyContingentPaymentMaximum	45000000	USD
CY2010Q3	lxrx	Symphony Contingent Payment Percentage SymphonyContingentPaymentPercentage	0.50
CY2014Q4	lxrx	Symphony Contingent Payment Total SymphonyContingentPaymentTotal	11500000	USD
CY2014Q4	lxrx	Symphony Contingent Paymentin Shares SymphonyContingentPaymentinShares	666111	shares
CY2017Q1	lxrx	Symphony Contingent Paymentin Shares SymphonyContingentPaymentinShares	659905	shares
CY2010Q3	lxrx	Symphony Payment In Stock Limitation SymphonyPaymentInStockLimitation	0.50
CY2010Q3	lxrx	Symphony Regulatory Approval Payment SymphonyRegulatoryApprovalPayment	15000000	USD
CY2010Q3	lxrx	Symphony Regulatory Approval Percentage Limit SymphonyRegulatoryApprovalPercentageLimit	0.50
CY2010Q3	lxrx	Symphony Regulatory Approval Reduction Percentage SymphonyRegulatoryApprovalReductionPercentage	0.50
	lxrx	Xermelo Intangible Assets Finite Lived XERMELOIntangibleAssetsFiniteLived	24700000	USD
CY2016Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-195000	USD
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	52877000	USD
CY2017Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	43857000	USD
CY2016Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	7492000	USD
CY2017Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	5014000	USD
CY2016Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	32114000	USD
CY2017Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	10959000	USD
CY2016Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	59875000	USD
CY2017Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	58337000	USD
CY2017Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-214000	USD
CY2016Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1411222000	USD
CY2017Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1430630000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3792000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4634000	USD
CY2016Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	4000	USD
CY2017Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	4000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	250000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	254000	USD
CY2017Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	400000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	600000	USD
CY2016Q4	us-gaap	Assets Assets	475625000	USD
CY2017Q2	us-gaap	Assets Assets	363513000	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	357874000	USD
CY2017Q2	us-gaap	Assets Current AssetsCurrent	247186000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	202989000	USD
CY2016Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	38410000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	46600000	USD
CY2017Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	30706000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-164579000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-15894000	USD
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	225000000	shares
CY2017Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	225000000	shares
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	105000	USD
CY2017Q2	us-gaap	Common Stock Value CommonStockValue	105000	USD
CY2016Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-38073000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-72440000	USD
CY2017Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-35009000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-69969000	USD
CY2016Q2	us-gaap	Contracts Revenue ContractsRevenue	20001000	USD
	us-gaap	Contracts Revenue ContractsRevenue	32495000	USD
CY2017Q2	us-gaap	Contracts Revenue ContractsRevenue	8104000	USD
	us-gaap	Contracts Revenue ContractsRevenue	25669000	USD
CY2016Q2	us-gaap	Cost Of Goods Sold CostOfGoodsSold	0	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	0	USD
CY2017Q2	us-gaap	Cost Of Goods Sold CostOfGoodsSold	537000	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	762000	USD
CY2017Q2	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	8.442
CY2014Q4	us-gaap	Debt Instrument Convertible Conversion Ratio1 DebtInstrumentConvertibleConversionRatio1	118.4553
CY2017Q2	us-gaap	Debt Instrument Fair Value DebtInstrumentFairValue	165500000	USD
CY2017Q2	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.0823
CY2016Q2	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2017Q2	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-8652000	USD
CY2016Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	63372000	USD
CY2017Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	63201000	USD
CY2016Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	48934000	USD
CY2017Q2	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	28308000	USD
CY2016Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	18675000	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	2101000	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements	-21013000	USD
CY2017Q2	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	10023000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1037000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1552000	USD
CY2016Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.37
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.70
CY2017Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.33
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.67
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	1443000	USD
CY2015Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	22815000	USD
CY2016Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	24258000	USD
CY2016Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	18912000	USD
CY2017Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	0	USD
CY2016Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	0	USD
CY2017Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	589000	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	12000	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	2000	USD
CY2016Q4	us-gaap	Goodwill Goodwill	44543000	USD
CY2017Q2	us-gaap	Goodwill Goodwill	44543000	USD
CY2017Q2	us-gaap	Guarantee Obligations Maximum Exposure GuaranteeObligationsMaximumExposure	3500000	USD
CY2016Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-38112000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-72995000	USD
CY2017Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-35059000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-78602000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-5818000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	22269000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	107000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2478000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	31934000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	20797000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	0	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	811000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	0	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	33000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1066000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-6296000	USD
CY2016Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	53357000	USD
CY2017Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	52768000	USD
CY2016Q2	us-gaap	Interest Expense InterestExpense	1638000	USD
	us-gaap	Interest Expense InterestExpense	3287000	USD
CY2017Q2	us-gaap	Interest Expense InterestExpense	1614000	USD
	us-gaap	Interest Expense InterestExpense	3202000	USD
	us-gaap	Interest Paid Net InterestPaidNet	3046000	USD
	us-gaap	Interest Paid Net InterestPaidNet	2956000	USD
CY2017Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	586000	USD
CY2017Q2	us-gaap	Inventory Gross InventoryGross	811000	USD
	us-gaap	Licenses Revenue LicensesRevenue	88000	USD
CY2017Q2	us-gaap	Liabilities Current LiabilitiesCurrent	133173000	USD
CY2016Q2	us-gaap	Licenses Revenue LicensesRevenue	88000	USD
CY2016Q4	us-gaap	Inventory Net InventoryNet	0	USD
CY2017Q2	us-gaap	Inventory Net InventoryNet	811000	USD
CY2017Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	200000	USD
CY2017Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	25000	USD
CY2016Q4	us-gaap	Liabilities Liabilities	318224000	USD
CY2017Q2	us-gaap	Liabilities Liabilities	257200000	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	475625000	USD
CY2017Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	363513000	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	164643000	USD
CY2017Q2	us-gaap	Licenses Revenue LicensesRevenue	57000	USD
	us-gaap	Licenses Revenue LicensesRevenue	64000	USD
CY2016Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	16280000	USD
CY2017Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	15156000	USD
CY2016Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	85167000	USD
CY2017Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	85383000	USD
CY2017Q2	us-gaap	Mortgage Loans On Real Estate Carrying Amount Of Mortgages MortgageLoansOnRealEstateCarryingAmountOfMortgages	15200000	USD
CY2004Q2	us-gaap	Mortgage Loans On Real Estate New Mortgage Loans MortgageLoansOnRealEstateNewMortgageLoans	34000000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-857000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2586000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-72104000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-91618000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-117721000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	99241000	USD
CY2016Q2	us-gaap	Net Income Loss NetIncomeLoss	-38112000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-72995000	USD
CY2017Q2	us-gaap	Net Income Loss NetIncomeLoss	-35059000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-69950000	USD
	us-gaap	New Accounting Pronouncement Or Change In Accounting Principle Effect Of Adoption Quantification NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification	0	USD
CY2016Q2	us-gaap	Operating Expenses OperatingExpenses	57110000	USD
	us-gaap	Operating Expenses OperatingExpenses	103475000	USD
CY2017Q2	us-gaap	Operating Expenses OperatingExpenses	45946000	USD
	us-gaap	Operating Expenses OperatingExpenses	106724000	USD
CY2016Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-37021000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-70892000	USD
CY2017Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-33893000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-76378000	USD
CY2016Q4	us-gaap	Other Assets Current OtherAssetsCurrent	3878000	USD
CY2017Q2	us-gaap	Other Assets Current OtherAssetsCurrent	10174000	USD
CY2016Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	461000	USD
CY2017Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	428000	USD
CY2016Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	39000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	555000	USD
CY2017Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	50000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-19000	USD
CY2016Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	805000	USD
CY2017Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	313000	USD
CY2016Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	547000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1184000	USD
CY2017Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	448000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	978000	USD
CY2014Q4	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	3400000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	621000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	1679000	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	219437000	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	59989000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	67000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	163000	USD
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2017Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2017Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2016Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2014Q4	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	87500000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	752000	USD
CY2016Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	48216000	USD
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	159393000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	19390000	USD
CY2017Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	18588000	USD
CY2017Q2	us-gaap	Revenues Revenues	12053000	USD
	us-gaap	Revenues Revenues	30346000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	85218000	USD
CY2017Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	26934000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	70515000	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1250363000	USD
CY2017Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1322304000	USD
CY2016Q2	us-gaap	Revenues Revenues	20089000	USD
	us-gaap	Revenues Revenues	32583000	USD
CY2016Q2	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	0	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	0	USD
CY2017Q2	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	3892000	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	4613000	USD
CY2016Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	8416000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	16814000	USD
CY2017Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	18475000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	33346000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	3792000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	4634000	USD
CY2016Q4	us-gaap	Short Term Investments ShortTermInvestments	299904000	USD
CY2017Q2	us-gaap	Short Term Investments ShortTermInvestments	200481000	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	752000	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	5427000	USD
	us-gaap	Stock Issued During Period Value Treasury Stock Reissued StockIssuedDuringPeriodValueTreasuryStockReissued	0	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	157401000	USD
CY2017Q2	us-gaap	Stockholders Equity StockholdersEquity	106313000	USD
CY2015Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	285850000	USD
CY2016Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	217333000	USD
CY2016Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	157401000	USD
CY2017Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	106313000	USD
CY2016Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	306000	shares
CY2017Q2	us-gaap	Treasury Stock Shares TreasuryStockShares	122000	shares
CY2016Q4	us-gaap	Treasury Stock Value TreasuryStockValue	3368000	USD
CY2017Q2	us-gaap	Treasury Stock Value TreasuryStockValue	1904000	USD
	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	621000	USD
	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	1679000	USD
CY2017Q2	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	2100000	USD
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	555000	USD
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-19000	USD
CY2016Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	103830000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	103756000	shares
CY2017Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	105300000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	104883000	shares
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Concentration of Credit Risk:</font><font style="font-family:inherit;font-size:10pt;"> Lexicon’s cash equivalents, investments and accounts receivable represent potential concentrations of credit risk. The Company attempts to minimize potential concentrations of risk in cash equivalents and investments by placing investments in high-quality financial instruments. The Company’s accounts receivable are unsecured and are concentrated in pharmaceutical and biotechnology companies located in Europe and the United States.  The Company has not experienced any significant credit losses to date.  </font></div></div>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of Estimates:</font><font style="font-family:inherit;font-size:10pt;"> The preparation of financial statements in conformity with U. S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0001062822-17-000046-index-headers.html	Edgar Link	pending
0001062822-17-000046-index.html	Edgar Link	pending
0001062822-17-000046.txt	Edgar Link	pending
0001062822-17-000046-xbrl.zip	Edgar Link	pending
exh311certificationofprinc.htm	Edgar Link	pending
exh312certificationofprinc.htm	Edgar Link	pending
exh321certificationofprinc.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
lxrx-20170630.xml	Edgar Link	completed
lxrx-20170630.xsd	Edgar Link	pending
lxrx-20170630_cal.xml	Edgar Link	unprocessable
lxrx-20170630_def.xml	Edgar Link	unprocessable
lxrx-20170630_lab.xml	Edgar Link	unprocessable
lxrx-20170630_pre.xml	Edgar Link	unprocessable
lxrx630201710-q.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$LXRX
LEXICON PHARMACEUTICALS, INC. Stock $lxrx

2017 Q3 Form 10-Q Financial Statement

#000106282217000046 Filed on August 01, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LXRX LEXICON PHARMACEUTICALS, INC. Stock $lxrx

2017 Q3 Form 10-Q Financial Statement

#000106282217000046 Filed on August 01, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LXRX
LEXICON PHARMACEUTICALS, INC. Stock $lxrx